Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest

Immunome, Inc. (NASDAQ:IMNMGet Rating) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 70,200 shares, a drop of 50.2% from the April 30th total of 141,100 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily trading volume, of 85,100 shares, the days-to-cover ratio is currently 0.8 days.

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new stake in shares of Immunome during the first quarter valued at about $80,000. Bank of America Corp DE acquired a new stake in shares of Immunome during the fourth quarter valued at about $81,000. First Republic Investment Management Inc. acquired a new stake in shares of Immunome during the first quarter valued at about $87,000. Marshall Wace LLP grew its stake in shares of Immunome by 27.6% during the fourth quarter. Marshall Wace LLP now owns 10,654 shares of the company’s stock valued at $138,000 after acquiring an additional 2,306 shares in the last quarter. Finally, Morgan Stanley grew its stake in shares of Immunome by 9,375.8% during the second quarter. Morgan Stanley now owns 11,371 shares of the company’s stock valued at $196,000 after acquiring an additional 11,251 shares in the last quarter. 23.97% of the stock is currently owned by institutional investors.

IMNM has been the topic of several research reports. Chardan Capital cut their target price on Immunome from $16.00 to $9.00 in a research report on Friday, May 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunome in a research report on Monday, May 9th. Finally, Zacks Investment Research raised Immunome from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Friday, May 13th.

NASDAQ:IMNM opened at $3.25 on Friday. The business’s 50-day moving average is $4.18 and its two-hundred day moving average is $8.94. Immunome has a 12 month low of $2.09 and a 12 month high of $27.80. The firm has a market capitalization of $39.41 million, a PE ratio of -1.19 and a beta of 0.03.

Immunome (NASDAQ:IMNMGet Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.96) EPS for the quarter. On average, research analysts predict that Immunome will post -2.96 EPS for the current fiscal year.

About Immunome (Get Rating)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Further Reading

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.